Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer.

Autor: El Demery M; Department of Medical Oncology, Cap d¿Or Clinic, La Seyne sur Mer, France., Demirdjian-Sarkissian G; Clinical Diagnostic Division, Thermo Fisher Scientific, Nimes, France., Thezenas S; Department of Biostatistics, Institut Régional du Cancer de Montpellier (ICM), Val d¿Aurelle, Montpellier, France., Jacot W; Department of Medical Oncology, Institut Régional du Cancer de Montpellier (ICM), Val d¿Aurelle, Montpellier, France., Laghzali Y; Department of Biostatistics, Institut Régional du Cancer de Montpellier (ICM), Val d¿Aurelle, Montpellier, France., Darbouret B; Clinical Diagnostic Division, Thermo Fisher Scientific, Nimes, France., Culine S; Hôpital Saint-Louis, APHP, Saint-Louis, France., Rebillard X; Clinique Beausoleil, Montpellier, France., Lamy PJ; Department of Biology and Oncogenetics, Institut Régional du Cancer de Montpellier (ICM), Val d¿Aurelle, Montpellier, 34298, France.
Jazyk: angličtina
Zdroj: Clinical and translational medicine [Clin Transl Med] 2014 Oct 28; Vol. 3, pp. 31. Date of Electronic Publication: 2014 Oct 28 (Print Publication: 2014).
DOI: 10.1186/s40169-014-0031-4
Abstrakt: Background: Urine markers have been studied extensively but there is a lack of blood prognostic markers in bladder cancer. MMP-7 is produced by stromal cells and by tumor cells and is overexpressed in a variety of epithelial and mesenchymal tumors. In this study, we assessed with an immunoassay we developed, the prognostic value of serum MMP-7 in a series of patients with advanced bladder cancer.
Methods: Serum samples were collected from 56 patients with advanced bladder cancer who were treated at the Montpellier Cancer Institute between March 2003 and December 2004. MMP-7 was quantified in serum samples by using a homogeneous sandwich fluoroimmunoassay we developed based on the time resolved amplified cryptate emission (TRACE) technology.
Results: The median overall survival of the study population was 2.2 years (95% CI, 1.4 to 3.0) with 1- and 5-year survival rates of 73% (95% CI, 59% to 82%) and 25% (95% CI, 14% to 37%), respectively. High MMP-7 serum levels were associated with poor survival. Using a cut-off value of 11.5 ng/mL, the median overall survival was 3.0 years (95% CI, 1.5 to 5.1) for patients with MMP-7 serum level <11.5 ng/mL and 1.3 years (95% CI, 0.8 to 2.5) for patients with serum level ?11.5 ng/mL. Multivariate analysis identified high MMP-7 serum concentration as an independent prognostic factor for survival in patients with advanced bladder cancer (R?=?2.1, 95% CI, 1.1 to 4.4).
Conclusions: Our results show that the MMP-7 serum concentration is an independent prognostic factor in patients with locally advanced and or metastatic bladder cancer.
Databáze: MEDLINE
Externí odkaz: